AstraZeneca Receives $1B for Covid-19 Vaccine
AstraZeneca recently announced they have received more than $1 billion from the U.S. Biomedical Advanced Research and Development Authority (BARDA) meant to “support the development, production and delivery of a Covid-19 vaccine.”
Pascal Soriot, CEO of AstraZeneca, released a statement citing the company’s collaboration with Oxford University “to turn their groundbreaking work into a medicine that can be produced on a global scale.” The statement offered hopeful sentiments over making the vaccine “quickly and widely available.”
The agreement between BARDA and AstraZeneca requires the latter to supply at least 400 million doses of the vaccine, AZD1222. It is currently undergoing clinical testing, and the company has announced its “capacity to produce 1 billion doses of the vaccine starting in the fall.”
AstraZeneca is a London-based company but is also working closely with international organizations like the World Health Organization to ensure widespread accessibility and implementation of the vaccine.
AstraZeneca started phase I and II of its clinical trials in April, and results of the 1,000 healthy volunteers aged 18 to 55 years are expected shortly. Given the results are positive, the company will continue with phase III of the trial, testing 30,000 participants and conducting a separate pediatric trial.